Pete, as far as valuation, this is from an article

Pete, as far as valuation, this is from an article the Washington Post just put up, about 10 drugs expected to be approved this year. The bashers keep trying to scare people about how high the bar supposedly is for FDA approval -- yet look at the low efficacy of this drug:

Quote:

---

5. Rova-T; AbbVie: $971 million

The latest cancer drug to join AbbVie’s all-star lineup, Rova-T could be the first targeted drug approved for highly lethal small-cell lung cancer, which kills 60,000 people a year. Clinical trials have found that it led to tumor shrinkage in 18 percent of patients and some clinical benefit in 41 percent of patients.

---

"SOME clinical benefit" -- not a very high bar to show "some" benefit. And not even half of patients.

Now contrast that to about the same percentage of patients NOT getting severe oral mucositis in IPIX's recent study, before formulation and dosing has been tweaked for maxiumum benefit. Do you think the FDA is going to approve a drug that gives "some" benefit, and not approve Brilacidin-OM which PREVENTS the condition?

Me neither.

Here's the full article
https://www.washingtonpost.com/news/powerpost...e407c0e9c5